Author Correction: Tau molecular diversity contributes to clinical heterogeneity in Alzheimer's disease

Simon Dujardin^{1

2}, Caitlin Commins¹, Aurelien Lathuiliere^{1

2}, Pieter Beerepoot^{2

3}, Analiese R Fernandes¹, Tarun V Kamath¹, Mark B De Los Santos¹, Naomi Klickstein¹, Diana L Corjuc¹, Bianca T Corjuc¹, Patrick M Dooley^{1

4}, Arthur Viode^{2

3}, Derek H Oakley^{1

2

4}, Benjamin D Moore^{1

2

5}, Kristina Mullin⁶, Dinorah Jean-Gilles⁷, Ryan Clark⁷, Kevin Atchison⁷, Renee Moore⁷, Lori B Chibnik^{1

2

8}, Rudolph E Tanzi^{2

6}, Matthew P Frosch^{2

4}, Alberto Serrano-Pozo^{1

2}, Fiona Elwood^{7

9}, Judith A Steen^{2

3}, Matthew E Kennedy⁷, Bradley T Hyman^{10

11}

Affiliations

¹ Alzheimer Research Unit, Department of Neurology, Massachusetts General Hospital, Charlestown, MA, USA.
² Harvard Medical School, Boston, MA, USA.
³ F.M. Kirby Neurobiology Center, Boston Children's Hospital, Boston, MA, USA.
⁴ C.S. Kubik Laboratory for Neuropathology, Massachusetts General Hospital, Boston, MA, USA.
⁵ Aquinnah Pharmaceuticals, Cambridge, MA, USA.
⁶ Genetics and Aging Research Unit, Department of Neurology, Massachusetts General Hospital, Charlestown, MA, USA.
⁷ Department of Neuroscience, Merck & Co., Boston, MA, USA.
⁸ Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
⁹ Novartis Institutes for BioMedical Research, Cambridge, MA, USA.
¹⁰ Alzheimer Research Unit, Department of Neurology, Massachusetts General Hospital, Charlestown, MA, USA. bhyman@mgh.harvard.edu.
¹¹ Harvard Medical School, Boston, MA, USA. bhyman@mgh.harvard.edu.

Published Erratum

Simon Dujardin et al. Nat Med. 2021 Feb.

. 2021 Feb;27(2):356.

doi: 10.1038/s41591-021-01251-7.

¹ Alzheimer Research Unit, Department of Neurology, Massachusetts General Hospital, Charlestown, MA, USA.
² Harvard Medical School, Boston, MA, USA.
³ F.M. Kirby Neurobiology Center, Boston Children's Hospital, Boston, MA, USA.
⁴ C.S. Kubik Laboratory for Neuropathology, Massachusetts General Hospital, Boston, MA, USA.
⁵ Aquinnah Pharmaceuticals, Cambridge, MA, USA.
⁶ Genetics and Aging Research Unit, Department of Neurology, Massachusetts General Hospital, Charlestown, MA, USA.
⁷ Department of Neuroscience, Merck & Co., Boston, MA, USA.
⁸ Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
⁹ Novartis Institutes for BioMedical Research, Cambridge, MA, USA.
¹⁰ Alzheimer Research Unit, Department of Neurology, Massachusetts General Hospital, Charlestown, MA, USA. bhyman@mgh.harvard.edu.
¹¹ Harvard Medical School, Boston, MA, USA. bhyman@mgh.harvard.edu.

No abstract available

Erratum for

Tau molecular diversity contributes to clinical heterogeneity in Alzheimer's disease.
Dujardin S, Commins C, Lathuiliere A, Beerepoot P, Fernandes AR, Kamath TV, De Los Santos MB, Klickstein N, Corjuc DL, Corjuc BT, Dooley PM, Viode A, Oakley DH, Moore BD, Mullin K, Jean-Gilles D, Clark R, Atchison K, Moore R, Chibnik LB, Tanzi RE, Frosch MP, Serrano-Pozo A, Elwood F, Steen JA, Kennedy ME, Hyman BT. Dujardin S, et al. Nat Med. 2020 Aug;26(8):1256-1263. doi: 10.1038/s41591-020-0938-9. Epub 2020 Jun 22. Nat Med. 2020. PMID: 32572268 Free PMC article.